DRUG · Unmapped registry intervention
Hyperpolarized Bicarbonate (13C)
Find medicine records ·
Find other trials using this name
Clinical trial
Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer
NCT05851365
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
PROCEDURE · Unmapped registry intervention
Magnetic Resonance imaging
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedMagnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: EARLY_PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Prostate Cancerverified · MONDO: prostate cancer
Localized Prostate Carcinomaunresolved
Interventions
Sponsors & collaborators
Robert Flavell, MD, PhDlead sponsor
U.S. Army Medical Research Acquisition Activitycollaborator
Bristol-Myers Squibbcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05851365 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.